1Suda T, Udagawa N,Nakamura I,et al . Modulation of osteoclast differentiation by local factor[J].J Bone, 1995;17:875.
2Olmos JM,De Vega T. Etidronate inhibits the production of IL-6 by osteoblast like cells Methods Find Exp[J].Clin Pharmrmacol, 1999,21:519-22.
3Dovio A, Masera RG, Sartori ML,et al .Autocrine up-regulation of glucocorticoid receptors by interleukin-6 in human osteoblast-like cells[J].CalcifTissue Int,2001;69(5):293-8.
4Erices A,Cnget P, Rojas C,et al .Gpl30 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells[J].Exp Cell Res,2002;280(1):24-32.
5Bellido T,O'Brien CA, Roberson PK,et al .Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines:A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cell[J].J Biol Chem, 1998;273
6Jilka RL,Weinstein RS,Bellido T, et al .Osteoblast programmed cell death (apoptosis):modulation by growth factors and cytokines[J].J Bone Miner Res, 1998,13(5):793-802.
7Scheidt-Nave C,Bismar H,Leidig-Bruckner G, et al . Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause[J].J Clin Endocrinol Metab,2001;86(5):2032-42.
8Ohmori S,Kanda K,Kawano S,et al .Effects of estrogen on tail suspension-induced disuse atrophy in ovariectomized rats:Evaluation of the expression of interleukin 6 mRNA in the femur[J].Environ Med,2001;45(1): 12-4.
9Hasegawa J,Nagashima M,Yamamoto M,et al . Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritias[J].J Rheumatol,2003;30(3):474-9.
10Insogna K,Mitnick M,Pascarella J,et al .Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women[J].J Bone Miner Res,2002;17(Suppl 2):N108-16.
3[2]GamcroP, GrinauxM, SeguimP, etal.claracterizatiou of immunoreaction forms of human osteocalcin generated n vivo and in vitro[J].J Bone Miner Res, 1994,9:255 - 60.
4[1]Garnero P, Dehmas P D. Assessment of the serum levels of bone alkaline phpsphatase with a new immunoradiometric assay in patients vwith metabolic bone disease[J].J Clin Endocrinol Metab, 1993,77:1046-52.[2]GamcroP, GrinauxM, SeguimP, etal.claracterizatiou of immunoreac tion forms of human osteocalcin generated in vivo and in vitro[J].J Bone Miner Res, 1994,9:255 - 60.
5[2]Gamero P, Grinauzx M, Demiaux B, et al. Measurement of serum osteocalcin with a human specific two- site immunoradiometric assay[J].J Bone Miner Res, 1992,7:1389- 97.
6[3]Piedra C, Torres R, Repado A, et al. Serun tartrate - resistant acid pho phatase and bone mineral content in post - roenopausal osteoporosis [ J ]. Calcif Tissue Int, 1989,45:58 - 65.
7[4]Cheung C K, Panesar N S, Haines C, et al. Immunoasay of tartrate - resistant acid phosphatase in senun[J].Clin Clem, 1995,41:679-85.
8[5]BondeM,GarneroP, FledeliusC,etal. Measurementofbonedegrdtion porducts in serum using antibodies reactive with an isonerized form of an 8 amino acid sequence of the C - telopeptide of type I collagen[J].J Bone Miner Res, 1997,12:1028 - 36.
9[6]BonadeM,Qvist P, FledeliusC, etal.Inmunaseayforqusrtifyingtype I collagen degradation products in tuine evaluated[J].Clin Chem, 1994,40:20229.
10[7]Riss B J, Hanseu A M, Jensen K, et al. Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture. A 15 - years followup study[J]. Bone, 1996,19:9- 17.
